Journal
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
Volume 11, Issue 5, Pages 679-684Publisher
OXFORD UNIV PRESS
DOI: 10.1017/S1461145708008468
Keywords
Atypical antipsychotics; dyslipidaemia; gene expression; schizophrenia; SREBP
Funding
- Research Council of Norway [151904, 175345, 147787, 167153]
- Western Norway Health Authority (Helse Vest RHF)
- Dr. Einar Martens fund
- Eastern Norway Health Authority [123/2004]
- Ulleval University Hospital
- University of Oslo
Ask authors/readers for more resources
Recent in-vitro studies show that antipsychotic drugs increase lipid biosynthesis through changes in gene expression. Based on these finding we compared the expression of two central lipid biosynthesis genes, fatty acid synthase (FASN) and stearoyl-CoA desaturase (SCD), in whole blood of olanzapine-treated and unmedicated patients. Patients with psychotic disorders were consecutively selected from an ongoing, naturalistic study, and divided into two groups according to the following criteria: (1) strict monotherapy with olanzapine (n=19) or (2) no current medication (n=19). The groups were matched on gender, race and body mass index. Blood lipid levels were examined, and gene expression in whole blood was assessed with quantitative real-time PCR. Expression of FASN (p=0.003) and SCD (p=0.002) was significantly up-regulated in olanzapine-treated compared to unmedicated patients. Transcriptional activation of lipid biosynthesis genes in peripheral blood cells of olanzapine-treated patients suggests a direct lipogenic action of antipsychotic drugs, which may be related to metabolic adverse effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available